Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$49.23 +1.9%	$51.48	$21.34 ▼ $58.40	$3.94B	-0.28	1.40 million shs	802,546 shs
STOK Stoke Therapeutics	$19.56 -0.6%	$13.15	$5.35 ▼ $19.91	$1.07B	1.15	807,226 shs	1.15 million shs
TLX Telix Pharmaceuticals	$12.48 +3.2%	$14.55	$10.50 ▼ $30.36	$4.22B	N/A	44,195 shs	161,764 shs
ZLAB Zai Lab	$35.04 +3.1%	$36.20	$17.50 ▼ $44.34	$3.89B	1.03	968,974 shs	456,200 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.71%	-3.59%	-6.92%	+4.16%	+83.26%
STOK Stoke Therapeutics	+1.86%	+14.62%	+45.03%	+110.26%	+32.97%
TLX Telix Pharmaceuticals	+10.21%	+10.01%	-25.74%	-27.17%	+1,208,999,900.00%
ZLAB Zai Lab	+1.46%	-2.69%	-8.14%	+8.52%	+94.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	4.036 of 5 stars	3.5	2.0	0.0	4.7	3.5	0.8	0.0
STOK Stoke Therapeutics	4.5659 of 5 stars	4.6	1.0	0.0	4.8	2.5	0.8	1.3
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	2.8362 of 5 stars	3.4	2.0	0.0	0.0	3.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$81.57	65.69% Upside
STOK Stoke Therapeutics	3.22	Buy	$25.57	30.73% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	78.95% Upside
ZLAB Zai Lab	2.83	Moderate Buy	$57.22	63.30% Upside

Current Analyst Ratings Breakdown

Latest STOK, ZLAB, AKRO, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	STOK Stoke Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$28.00
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/11/2025	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $69.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
STOK Stoke Therapeutics	$199.89M	5.36	N/A	N/A	$6.11 per share	3.20
TLX Telix Pharmaceuticals	$516.72M	8.17	$0.13 per share	96.07	$1.12 per share	11.14
ZLAB Zai Lab	$427.80M	9.10	N/A	N/A	$7.13 per share	4.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
STOK Stoke Therapeutics	-$88.98M	$0.85	23.01	N/A	N/A	26.25%	18.32%	15.48%	11/4/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	26.00	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	-$257.10M	-$2.04	N/A	N/A	N/A	-49.68%	-27.32%	-18.85%	N/A

Latest STOK, ZLAB, AKRO, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	ZLAB Zai Lab	-$0.37	-$0.37	N/A	-$0.37	$125.66 million	$109.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.02	12.66	12.66
STOK Stoke Therapeutics	N/A	6.98	6.98
TLX Telix Pharmaceuticals	0.99	2.78	2.66
ZLAB Zai Lab	N/A	3.12	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
STOK Stoke Therapeutics	N/A
TLX Telix Pharmaceuticals	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
STOK Stoke Therapeutics	9.50%
TLX Telix Pharmaceuticals	N/A
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
STOK Stoke Therapeutics	100	54.80 million	49.59 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

STOK, ZLAB, AKRO, and TLX Headlines

Recent News About These Companies

Brokerages Set Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Price Target at $57.22

August 22 at 2:47 AM | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Insider Sells $240,669.84 in Stock

August 21 at 6:29 PM | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

August 21 at 4:13 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Down 5.9% on Insider Selling

August 21 at 2:17 AM | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $50,933.96 in Stock

August 20 at 6:18 PM | marketbeat.com

MY.Alpha Management HK Advisors Ltd Purchases New Shares in Zai Lab Limited Unsponsored ADR $ZLAB

August 20 at 8:06 AM | marketbeat.com

Zai Lab Points up as Chinese Gov’t Okays Tumor Treatment

August 19 at 8:34 PM | baystreet.ca

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

August 19 at 7:30 AM | businesswire.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 1,438 Shares of Stock

August 19 at 5:01 AM | insidertrades.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 46,387 Shares of Stock

August 16, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 20,346 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 16, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Sells 3,000 Shares of Stock

August 14, 2025 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $139,304.96 in Stock

August 14, 2025 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares

August 14, 2025 | marketbeat.com

Ying Du Sells 50,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

August 14, 2025 | marketbeat.com

Zai Lab Establishes Oncology Scientific Advisory Board

August 13, 2025 | finance.yahoo.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Rafael Amado Sells 3,000 Shares

August 13, 2025 | insidertrades.com

Zai Lab Ltd’s Earnings Call Highlights Growth and Profitability Path

August 13, 2025 | msn.com

US Bancorp DE Has $664,000 Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 12, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Here's What Analysts Are Forecasting For Zai Lab Limited (NASDAQ:ZLAB) After Its Second-Quarter Results

August 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, ZLAB, AKRO, and TLX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$49.23 +0.94 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$49.03 -0.20 (-0.41%)

As of 06:31 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Stoke Therapeutics NASDAQ:STOK

$19.56 -0.12 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$19.65 +0.09 (+0.46%)

As of 06:46 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$12.48 +0.39 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$12.54 +0.06 (+0.52%)

As of 06:15 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Zai Lab NASDAQ:ZLAB

$35.04 +1.05 (+3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$35.09 +0.05 (+0.14%)

As of 04:57 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time